Minocycline in the eradication of Helicobacter pylori infection: A systematic review and meta-analysis

被引:1
作者
Zhou, Kai [1 ]
Li, Cai-Ling [1 ]
Zhang, Hua [1 ]
Suo, Bao-Jun [1 ]
Zhang, Yu-Xin [1 ]
Ren, Xin-Lu [1 ]
Wang, Yu-Xin [1 ]
Mi, Chang-Min [1 ]
Ma, Ling-Ling [1 ]
Zhou, Li-Ya [1 ]
Tian, Xue-Li [1 ]
Song, Zhi-Qiang [1 ]
机构
[1] Peking Univ Third Hosp, Dept Gastroenterol, 49 North Garden Rd, Beijing 100191, Peoples R China
基金
中国国家自然科学基金; 北京市自然科学基金;
关键词
Helicobacter pylori; Minocycline; Eradication; Safety; Resistance; 2ND-LINE REGIMENS; TETRACYCLINE; BISMUTH; 1ST-LINE; METRONIDAZOLE; RESISTANCE; THERAPY; CLARITHROMYCIN; ESOMEPRAZOLE; ANTIBIOTICS;
D O I
10.3748/wjg.v30.i17.2354
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND Difficulty in obtaining tetracycline, increased adverse reactions, and relatively complicated medication methods have limited the clinical application of the classic bismuth quadruple therapy. Therefore, the search for new alternative drugs has become one of the research hotspots. In recent years, minocycline, as a semisynthetic tetracycline, has demonstrated good potential for eradicating Helicobacter pylori (H. pylori) infection, but the systematic evaluation of its role remains lacking. AIM To explore the efficacy, safety, and compliance of minocycline in eradicating H. pylori infection. METHODS We comprehensively retrieved the electronic databases of PubMed, Embase, Web of Science, China National Knowledge Infrastructure, SinoMed, and Wanfang database as of October 30, 2023, and finally included 22 research reports on H. pylori eradication with minocycline-containing regimens as per the inclusion and exclusion criteria. The eradication rates of H. pylori were calculated using a fixed or a random effect model, and the heterogeneity and publication bias of the studies were measured. RESULTS The single-arm meta-analysis revealed that the minocycline-containing regimens achieved good overall H. pylori eradication rates, reaching 82.3% [95% confidence interval (CI): 79.7%-85.1%] in the intention-to-treat analysis and 90.0% (95%CI: 87.7%-92.4%) in the per-protocol analysis. The overall safety and compliance of the minocycline-containing regimens were good, demonstrating an overall incidence of adverse reactions of 36.5% (95%CI: 31.5%-42.2%). Further by traditional meta-analysis, the results showed that the minocycline-containing regimens were not statistically different from other commonly used eradication regimens in eradication rate and incidence of adverse effects. Most of the adverse reactions were mild to moderate and well-tolerated, and dizziness was relatively prominent in the minocycline-containing regimens (16%). CONCLUSION The minocycline-containing regimens demonstrated good efficacy, safety, and compliance in H. pylori eradication. Minocycline has good potential to replace tetracycline for eradicating H. pylori infection.
引用
收藏
页码:2354 / 2368
页数:16
相关论文
共 46 条
  • [21] [李梦迪 Li Mengdi], 2019, [中华消化杂志, Chinese Journal of Digestion], V39, P812
  • [22] Susceptibility-guided vs. empirical 10-day quadruple treatment for Helicobacter pylori-infected patients: A prospective clinical trial of first-line therapy
    Li, Peiwei
    Jin, Jing
    Chen, Yan
    Ma, Jianjuan
    Du, Qin
    Han, Yuehua
    [J]. FRONTIERS IN MICROBIOLOGY, 2022, 13
  • [23] Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection
    Liu, Wen Zhong
    Xie, Yong
    Lu, Hong
    Cheng, Hong
    Zeng, Zhi Rong
    Zhou, Li Ya
    Chen, Ye
    Wang, Jiang Bin
    Du, Yi Qi
    Lu, Nong Hua
    [J]. HELICOBACTER, 2018, 23 (02)
  • [24] Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report
    Malfertheiner, P.
    Megraud, F.
    O'Morain, C. A.
    Gisbert, J. P.
    Kuipers, E. J.
    Axon, A. T.
    Bazzoli, F.
    Gasbarrini, A.
    Atherton, J.
    Graham, D. Y.
    Hunt, R.
    Moayyedi, P.
    Rokkas, T.
    Rugge, M.
    Selgrad, M.
    Suerbaum, S.
    Sugano, K.
    El-Omar, E. M.
    [J]. GUT, 2017, 66 (01) : 6 - 30
  • [25] Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report
    Malfertheiner, Peter
    Megraud, Francis
    Rokkas, Theodore
    Gisbert, Javier P.
    Liou, Jyh-Ming
    Schulz, Christian
    Gasbarrini, Antonio
    Hunt, Richard H.
    Leja, Marcis
    O'Morain, Colm
    Rugge, Massimo
    Suerbaum, Sebastian
    Tilg, Herbert
    Sugano, Kentaro
    El-Omar, Emad M.
    [J]. GUT, 2022, 71 (09) : 1724 - 1762
  • [26] A Review of Systemic Minocycline Side Effects and Topical Minocycline as a Safer Alternative for Treating Acne and Rosacea
    Martins, Ana M.
    Marto, Joana M.
    Johnson, Jodi L.
    Graber, Emmy M.
    [J]. ANTIBIOTICS-BASEL, 2021, 10 (07):
  • [27] Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection
    Murakami, K
    Sato, R
    Okimoto, T
    Watanabe, K
    Nasu, M
    Fujioka, T
    Kodama, M
    Abe, T
    Sato, S
    Arita, T
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 (01) : 262 - 267
  • [28] Functional, biophysical, and structural bases for antibacterial activity of tigecycline
    Olson, Matthew W.
    Ruzin, Alexey
    Feyfant, Eric
    Rush, Thomas S., III
    O'Connell, John
    Bradford, Patricia A.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (06) : 2156 - 2166
  • [29] Pu N., 2018, Zhongguo Laonianxue Zazhi, V38, P5713
  • [30] Comparative safety of tetracycline, minocycline, and doxycycline
    Shapiro, LE
    Knowles, SR
    Shear, NH
    [J]. ARCHIVES OF DERMATOLOGY, 1997, 133 (10) : 1224 - 1230